57005-71-7

Usage

Uses

Used in Pharmaceutical Synthesis:
2-(4-METHYL-1-PIPERAZINYL)-4-PYRIMIDINAMINE is used as an intermediate in the synthesis of pharmaceutical compounds, contributing to the development of new drugs with therapeutic benefits.
Used in Cancer Treatment:
In the field of oncology, 2-(4-METHYL-1-PIPERAZINYL)-4-PYRIMIDINAMINE is used as a potential anti-tumor agent for the treatment of various types of cancer, leveraging its anti-tumor properties to combat the disease.
Used in Anti-Viral Therapy:
2-(4-METHYL-1-PIPERAZINYL)-4-PYRIMIDINAMINE is utilized in the development of anti-viral drugs, targeting viral infections and mitigating their impact on human health.
Used in Central Nervous System Disorders:
In the pharmaceutical industry, 2-(4-METHYL-1-PIPERAZINYL)-4-PYRIMIDINAMINE is used as a component in the development of drugs targeting central nervous system disorders, aiming to improve treatment options for neurological conditions.

InChI:InChI=1/C9H15N5/c1-13-4-6-14(7-5-13)9-11-3-2-8(10)12-9/h2-3H,4-7H2,1H3,(H2,10,11,12)

Upstream product

• 109-01-3 1-methyl-piperazine 
• 7461-50-9 2-chloropyrimidin-4-amine 

Relevant academic research and scientific papers

Optimization of Physicochemical Properties for 4-Anilinoquinoline Inhibitors of Plasmodium falciparum Proliferation

We recently reported the medicinal chemistry reoptimization of a known human tyrosine kinase inhibitor, lapatinib, against a variety of parasites responsible for numerous tropical diseases, including human African trypanosomiasis (Trypanosoma brucei), Chagas disease (T. cruzi), Leishmaniasis (Leishmania spp.), and malaria (Plasmodium falciparum). Herein, we report our continuing efforts to optimize this series against P. falciparum. Through the design of a library of compounds focused on reducing the lipophilicity and molecular weight, followed by an SAR exploration, we have identified NEU-1953 (40). This compound is a potent inhibitor of P. falciparum with an improved ADME profile over the previously reported compound, NEU-961 (3).

INHIBITORS OF MUTANT FORMS OF EGFR

The present disclosure provides a compound represented by structural formula (I) : or a pharmaceutically acceptable salt thereof useful for treating a cancer.

Peptide deformylase inhibitors

The present invention relates to a compound of Formula (I): or a pharmaceutically acceptable salt thereof, corresponding pharmaceutical compositions, compound preparation and treatment methods directed to bacterial infections and inhibition of bacterial peptide deformylase (PDF) activity.

PEPTIDE DEFORMYLASE INHIBITORS

The present invention relates to a compound of Formula (I): or a pharmaceutically acceptable salt thereof, corresponding pharmaceutical compositions, compound preparation and treatment methods directed to bacterial infections and inhi-bition of bacterial peptide deformylase (PDF) activity

CYTOKINE INHIBITORS

The present invention provides low molecular weight compounds useful as cytokine inhibitors, and compositions thereof. In particular, compounds of the invention are useful as anti-inflammatory agents. There are further provided methods for the preparation of such agents and their use in preventing or treating conditions mediated by cytokines, such as for example arthritis, pain, cardiovascular disease and cancer.